Document text
Principal Investigator: Rebecca Ashare
Organization: STATE UNIVERSITY OF NEW YORK AT BUFFALO
Fiscal Year: 2024
Award: $599,442
Funding agency: National Cancer Institute
Project Abstract
Up to 40% of patients report using cannabis for symptom management during and after cancer treatments
despite gaps in our understanding of its longitudinal therapeutic uses and harms. Simultaneously, immuno-
oncology is a rapidly advancing field of cancer treatment. Nearly 44% of cancer patients across 20 tumor types
receive treatments with immunotherapy, notably Immune Checkpoint Inhibitors (ICIs), which can lead to
persistent changes in the immune system for months or even years. Given cannabis also has immunomodulatory
effects, there is a critical need to generate long-term data on the impact of cannabis use on longitudinal benefits
and harms, immune function, and disease progression in cancer patients treated with ICIs. This proposal builds
upon our existing program of research. Our team has conducted 4 NCI-funded projects regarding cannabis use
in cancer patients, including 3 large cross-sectional surveys of cannabis use among patients treated at 3 NCI
designated cancer centers. Across sites, 26% (n=831 of 3,169) of cancer patients reported using cannabis during
treatment. However, the rate was considerably higher among patients treated with immunotherapy (32%). The
overarching goal of this study is to advance the science regarding the longitudinal benefits and harms of
cannabis use among those treated with ICIs for cancer. We propose a multi-site, 12-month prospective cohort
study (N=450; 150 per site) with cancer patients treated with ICI (within 3 months): 225 cannabis users (regular
weekly use in the prior month) and 225 cannabis non-users (no use in the past 6 months). Cannabis use,
benefits, and harms will be assessed via ecological momentary assessment (collected 7 days/time point; 49
days total), patient reported outcomes will be assessed via online/phone surveys, and routine clinical data will
be extracted from electronic medical records. Among a subset of 60 patients who have not yet started ICI
treatment (30 cannabis users; 30 non-users), we will examine immunological markers (e.g., TNF-α, IL-6, CRP)
at baseline (prior to starting ICI), 2, 6, & 12 months. The Specific Aims are to: 1) assess benefits (pain severity
& interference, sleep disturbance, anxiety, quality of life) and harms (difficulty concentrating, impaired memory,
dizziness, fatigue) of cannabis use over time; 2) test whether cannabis use over time moderates the associations
between neighborhood disadvantage (Area Deprivation Index) and benefits and harms in Aim 1; & 3) among a
subset of 60 patients with non-skin solid malignancies who have not yet started ICI, explore the association of
cannabis use with disease progression and immunological markers. This timely and comprehensive study, in
response to RFA-CA-22-052, will fill critical gaps in knowledge about longitudinal benefits and harms of cannabis
use in persons treated with ICIs. The strong multidisciplinary team brings the requisite expertise in cancer
symptom management, medical cannabis, health equity, oncology, immunology, and substance misuse. In
collaboration with other funded U01s and U24, this research will have a sustained impact on the science of
cancer symptom management and ultimately improve patient care and safety.
Terms: <(TNF)-α><Adverse effects><Anxiety><Area><B cell differentiation factor><B cell stimulating factor 2><B-Cell Differentiation Factor><B-Cell Differentiation Factor-2><B-Cell Stimulatory Factor-2><BCDF><BSF-2><BSF2><Biological><Blood Cell Count><Blood Cell Number><CSF3><CSF3 gene><Cachectin><Cancer Patient><Cancer Science><Cancer Treatment><Cancers><Cannabis><Cellular Immune Function><Checkpoint inhibitor><Clinical><Clinical Data><Co-Stimulator><Cognitive><Collaborations><Computerized Medical Record><Consumption><Costimulator><Cross Sectional Analysis><Cross-Sectional Analyses><Cross-Sectional Studies><Cross-Sectional Survey><D.C. Washington><DC Washington><Data><Decrease disparity><Disease><Disease Frequency Surveys><Disease Progression><Disorder><Disparities><Disparity><District of Columbia><Dizziness><Ecological momentary assessment><Electronic Medical Record><Epidermal Thymocyte Activating Factor><Exhibits><Fatigue><Funding><G-CSF><GCSF><GM-CSF><Goals><Granulocyte-Macrophage Colony-Stimulating Factor><HPGF><Hepatocyte-Stimulating Factor><Histamine-Producing Cell-Stimulating Factor><Hybridoma Growth Factor><IFN-beta 2><IFNB2><IL-2><IL-6><IL2 Protein><IL6 Protein><Immune Markers><Immune checkpoint inhibitor><Immune mediated therapy><Immune system><Immunologic Markers><Immunologically Directed Therapy><Immunology><Immunomodulation><Immunooncology><Immunotherapy><Individual><Interdisciplinary Research><Interdisciplinary Study><Interleukin 2><Interleukin 2 Precursor><Interleukin II><Interleukin-2><Interleukin-6><Interleukine 2><Interleukine 2 Precursor><Interleukine II><Knowledge><Lack of Energy><Legal><Link><Longitudinal Studies><Lower disparity><Lymphocyte Mitogenic Factor><MGC45931><MGI-2><Macrophage-Derived TNF><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Measures><Medical Marijuana><Medicinal Marijuana><Memory Deficit><Memory impairment><Mental Health><Mental Hygiene><Methods><Mitogenic Factor><Molgramostin><Monocyte-Derived TNF><Moods><Multidisciplinary Collaboration><Multidisciplinary Research><Myeloid Differentiation-Inducing Protein><NCI-Designated Cancer Center><Oncologist><Oncology><Oncology Cancer><Outcome><Pain><Painful><Patient Care><Patient Care Delivery><Patient Outcomes Assessments><Patient Reported Measures><Patient Reported Outcomes><Patients><Performance><Persons><Phone><Plasmacytoma Growth Factor><Prevalence><Prospective, cohort study><Psychological Health><QOL><Qualifying><Quality of life><Renal function><Reporting><Research><Role><Sampling><Schedule><Science><Severities><Site><Sleep><Sleep disturbances><Solid><Survey Instrument><Surveys><Symptoms><T cell growth factor><T-Cell Growth Factor><T-Cell Stimulating Factor><TC-GM-CSF><THC co-use><THC use><TNF><TNF A><TNF Alpha><TNF gene><TNF-α><TNFA><TNFα><Telephone><Testing><Tetrahydrocannabinol co-use><Tetrahydrocannabinol use><Therapeutic><Therapeutic Uses><Thymocyte Stimulating Factor><Time><Tumor Necrosis Factor><Tumor Necrosis Factor-alpha><Tumor-Cell Human GM Colony-Stimulating Factor><aberrant sleep><anti-cancer immunotherapy><anti-cancer therapy><anticancer immunotherapy><biologic><cancer immunotherapy><cancer progression><cancer therapy><cancer-directed therapy><cannabis use><cannabis use disorder><cannabis user><care for patients><care of patients><caring for patients><check point immunotherapy><check point inhibitor therapy><check point inhibitory therapy><check point therapy><checkpoint immunotherapy><checkpoint inhibitor therapy><checkpoint inhibitory therapy><checkpoint therapy><cognitive task><community level disadvantage><deprivation><disadvantaged community><disparity reduction><disrupted sleep><disturbed sleep><electronic data><evidence base><granulocyte macrophage colony stimulating factor><health equity><immune check point inhibitor><immune check point therapy><immune checkpoint therapy><immune function><immune modulation><immune regulation><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based biomarkers><immune-based cancer therapies><immune-based therapies><immune-based treatments><immune-oncology><immuno oncology><immuno therapy><immunologic reactivity control><immunological biomarkers><immunological markers><immunology oncology><immunomodulatory><immunoregulation><immunoregulatory><immunotherapy for cancer><immunotherapy of cancer><impaired sleep><improved><improvement on sleep><indexing><interferon beta 2><irregular sleep><kidney function><liver function><long-term study><longitudinal outcome studies><longterm study><malignancy><manage symptom><marijuana use><marijuana use and disorder><marijuana use disorder><marijuana user><medical cannabis><medicinal cannabis><memory dysfunction><mitigate disparity><multidisciplinary><neighborhood barrier><neighborhood disadvantage><neighborhood-level barrier><neighborhood-level disadvantage><neoplasm progression><neoplasm/cancer><neoplastic progression><oncoimmunology><patient safety><patient subclass><patient subcluster><patient subgroups><patient subpopulations><patient subsets><patient subtypes><programs><progression biomarker><progression marker><prospective><reduce disparity><reduction in disparity><response><secondary outcome><side effect><sleep disruption><sleep dysregulation><sleep improvement><social health determinants><social role><substance misuse><symptom management><therapeutic cannabis><therapeutic marijuana><tumor><tumor progression><virtual>